Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1,763 INR | +0.08% | +0.91% | -8.34% |
Apr. 08 | Nicomac Machinery and RP Advisory Services Reportedly Likely to Sell 4.4% Stake in Gland Pharma via Block Deals | CI |
Apr. 08 | Gland Pharma Gets US FDA Approval for Eribulin Mesylate Injection | MT |
Sales 2024 * | 56.56B 677M | Sales 2025 * | 63.32B 758M | Capitalization | 291B 3.48B |
---|---|---|---|---|---|
Net income 2024 * | 8.48B 102M | Net income 2025 * | 11.02B 132M | EV / Sales 2024 * | 4.65 x |
Net cash position 2024 * | 27.46B 329M | Net cash position 2025 * | 31.74B 380M | EV / Sales 2025 * | 4.09 x |
P/E ratio 2024 * |
34.2
x | P/E ratio 2025 * |
26.3
x | Employees | 4,585 |
Yield 2024 * |
0.1% | Yield 2025 * |
0.19% | Free-Float | 38.38% |
Latest transcript on Gland Pharma Limited
1 day | +0.08% | ||
1 week | +0.91% | ||
Current month | -4.28% | ||
1 month | -0.54% | ||
3 months | -10.27% | ||
6 months | +9.67% | ||
Current year | -8.34% |
Managers | Title | Age | Since |
---|---|---|---|
Srinivas Sadu
CEO | Chief Executive Officer | 55 | 99-12-31 |
Director of Finance/CFO | - | 19-09-29 | |
C. S. Venkatesan
CTO | Chief Tech/Sci/R&D Officer | - | 97-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Fang Yao
BRD | Director/Board Member | 54 | 22-03-09 |
Srinivas Sadu
CEO | Chief Executive Officer | 55 | 99-12-31 |
Yiu Kwan Lau
CHM | Chairman | 69 | 19-06-09 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-19 | 1,763 | +0.08% | 3 557 |
24-04-18 | 1,762 | +0.70% | 7,084 |
24-04-16 | 1,750 | -0.09% | 4,308 |
24-04-15 | 1,751 | +0.22% | 8,892 |
24-04-12 | 1,747 | -2.56% | 31,325 |
Delayed Quote Bombay S.E., April 19, 2024 at 05:46 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+27.97% | 672B | |
+23.74% | 550B | |
-7.02% | 351B | |
+14.85% | 317B | |
+6.25% | 292B | |
+1.98% | 211B | |
-0.51% | 203B | |
-10.27% | 194B | |
-11.81% | 144B |
- Stock Market
- Equities
- GLAND Stock
- GLAND Stock